Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2309 ARTÍCULOS , VIENDO DEL 601 AL 615

The Role of microRNAs in Epigenetic Regulation of Signaling Pathways in Neurological Pathologies

Tregub PP, Ibrahimli I, Averchuk AS, Salmina AB, Litvitskiy PF, Manasova ZS, Popova IA.

Int J Mol Sci. 2023 Aug 17;24(16):12899. doi: 10.3390/ijms241612899.

A New Perspective for the Treatment of Alzheimer's Disease: Exosome-like Liposomes to Deliver Natural Compounds and RNA Therapies

Ribeiro J, Lopes I, Gomes AC.

Molecules. 2023 Aug 11;28(16):6015. doi: 10.3390/molecules28166015.

Molecular and functional characteristics of receptor-interacting protein kinase 1 (RIPK1) and its therapeutic potential in Alzheimer's disease

Pati S, Singh Gautam A, Dey M, Tiwari A, Kumar Singh R.

Drug Discov Today. 2023 Dec;28(12):103750. doi: 10.1016/j.drudis.2023.103750. Epub 2023 Aug 24.

Function and regulation of cis P-tau in the pathogenesis and treatment of conventional and nonconventional tauopathies

Wang R, Lu KP, Zhou XZ.

J Neurochem. 2023 Sep;166(6):904-914. doi: 10.1111/jnc.15909. Epub 2023 Aug 28.

Microglia-Astrocyte Communication in Alzheimer's Disease

Wu Y, Eisel ULM.

J Alzheimers Dis. 2023;95(3):785-803. doi: 10.3233/JAD-230199.

Evaluation of Efficacy and Safety Using Low Dose Radiation Therapy with Alzheimer's Disease: A Protocol for Multicenter Phase II Clinical Trial

Kim DY, Kim JS, Seo YS, Park WY, Kim BH, Hong EH, Kim JY, Cho SJ, Rhee HY, Kim A, Kim KY, Oh DJ, Chung WK.

J Alzheimers Dis. 2023;95(3):1263-1272. doi: 10.3233/JAD-230241.

Unleashing the Power of Bayesian Re-Analysis: Enhancing Insights into Lecanemab (Clarity AD) Phase III Trial Through Informed t-Test

Costa T, Premi E, Liloia D, Cauda F, Manuello J.

J Alzheimers Dis. 2023;95(3):1059-1065. doi: 10.3233/JAD-230589.

Management of neuropsychiatric symptoms in dementia

Devanand DP.

Curr Opin Neurol. 2023 Oct 1;36(5):498-503. doi: 10.1097/WCO.0000000000001199. Epub 2023 Aug 7.

Semorinemab in Mild-to-Moderate Alzheimer Disease: A Glimmer of Hope Though Cautions Remain

Edland SD, Llibre-Guerra JJ.

Neurology. 2023 Oct 3;101(14):593-594. doi: 10.1212/WNL.0000000000207861. Epub 2023 Aug 29.

A state-of-the-art review on miRNA in prevention and treatment of Alzheimer's disease

Guo X.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023 Aug 25;52(4):485-498. doi: 10.3724/zdxbyxb-2023-0324.

Application of P7C3 Compounds to Investigating and Treating Acute and Chronic Traumatic Brain Injury

Sridharan PS, Miller E, Pieper AA.

Neurotherapeutics. 2023 Oct;20(6):1616-1628. doi: 10.1007/s13311-023-01427-8. Epub 2023 Aug 31.

Crosstalk between NLRP3 inflammasome and calpain in Alzheimer's disease

Mamsa R, Prabhavalkar KS, Bhatt LK.

Eur J Neurosci. 2023 Oct;58(7):3719-3731. doi: 10.1111/ejn.16139. Epub 2023 Aug 31.

Alzheimer's Disease in Diabetic Patients: A Lipidomic Prospect

Makki BE, Rahman S.

Neuroscience. 2023 Oct 15;530:79-94. doi: 10.1016/j.neuroscience.2023.08.033. Epub 2023 Aug 29.

Comparative analysis of early neurodegeneration signs in a mouse model of Alzheimer's disease-like pathology induced by two types of the central (Intracerebroventricular vs. Intrahippocampal) administration of Aβ(25-35) oligomers

Belichenko VM, Bashirzade AA, Tenditnik MV, Dubrovina NI, Akopyan AA, Ovsyukova MV, Fedoseeva LA, Pupyshev AB, Aftanas LI, Amstislavskaya TG, Tikhonova MA.

Behav Brain Res. 2023 Oct 2;454:114651. doi: 10.1016/j.bbr.2023.114651. Epub 2023 Aug 30.

Exploring the therapeutic potential of natural compounds for Alzheimer's disease: Mechanisms of action and pharmacological properties

Liu J, Li T, Zhong G, Pan Y, Gao M, Su S, Liang Y, Ma C, Liu Y, Wang Q, Shi Q.

Biomed Pharmacother. 2023 Oct;166:115406. doi: 10.1016/j.biopha.2023.115406. Epub 2023 Sep 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias